|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Stock-based compensation | |||||
| Change in fair value of earn-out liabilities | |||||
| Change in fair value of derivative warrant liabilities | |||||
| Change in fair value of forward contract | |||||
| Impairment of deferred offering costs | |||||
| Accretion of available-for-sale securities | |||||
| Loss on extinguishment of debt | |||||
| Amortization of debt issuance costs, commitment fees and accretion of final payment fees | |||||
| Non-cash lease expense | |||||
| Goodwill impairment | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Prepaid expenses, other current assets and other assets | |||||
| Deferred revenue | |||||
| Accounts payable | |||||
| Accrued expenses and operating lease liabilities | |||||
| Other liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of property and equipment | |||||
| Purchases of available-for-sale securities | |||||
| Maturities of available-for-sale securities | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Transaction costs paid directly by Rigetti | |||||
| Proceeds from issuance of notes payable | |||||
| Payments of principal of notes payable | |||||
| Payments of debt issuance costs | |||||
| Payment of loan and security agreement exit fees | |||||
| Net payments of tax withholdings on sell-to-cover equity award transactions | |||||
| Proceeds from sale of common stock through Common Stock Purchase Agreement | |||||
| Proceeds from sale of common stock through ATM Offerings | |||||
| Proceeds from sale of common stock through registered direct offering | |||||
| Proceeds from sale of common stock from Quanta private placement transaction | |||||
| Payments of offering costs | |||||
| Proceeds from issuance of common stock upon exercise of stock options and warrants | |||||
| Net proceeds (payments) from tax withholdings on sell-to-cover equity award transactions | |||||
| Proceeds from issuance of common stock upon exercise of stock options | |||||
| Proceeds from issuance of common stock upon exercise of warrants | |||||
| Net cash provided by financing activities | |||||
| Effects of exchange rate changes on cash and cash equivalents | |||||
| Net decrease in cash and cash equivalents | |||||
| Cash and cash equivalents - beginning of period | |||||
| Cash and cash equivalents - end of period | |||||
| Supplemental disclosures of other cash flow information: | |||||
| Cash paid for interest | |||||
| Non-cash investing and financing activities: | |||||
| Initial fair value of earn-out liability acquired in merger | |||||
| Reclassification of loan and security agreement warrants to equity | |||||
| Settlement of the first tranche of forward contract | |||||
| Capitalization of deferred costs to equity upon share issuance | |||||
| Purchases of property and equipment recorded in accounts payable | |||||
| Purchases of property and equipment recorded in accrued expenses | |||||
| Reclassification of earn-out liabilities to additional paid-in capital for vesting of Sponsor Vesting Shares | |||||
| Reclassification of derivative liabilities to additional paid-in capital due to exercise of Public Warrants | |||||
| Unrealized gain on short term investments | |||||
| Right-of-use assets recorded on adoption of ASU 2016-02 | |||||
| Operating lease liabilities recorded on adoption of ASU 2016-02 | |||||
| Lease liabilities arising from obtaining right-of-use assets | |||||
Loading...